Pharma major plummets over 10% after third trial disappointment in a week

Novartis shares tanked 10% on Tuesday after the pharmaceutical giant said its del-desiran drug for muscle-wasting disorder failed in a late-stage trial.

The company's stock was last seen down by 10%, as investors reacted to what was its third drug trial setback in a week.

Novartis stock

This is a developing story. Please refresh for updates.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.